Phase I/IIa trial of 18F-prostate specific membrane antigen (PSMA) 1007 PET/CT in healthy volunteers and prostate cancer patients.

Ukihide TateishiKoichiro KimuraJunichi TsuchiyaDaisuke KanoTadashi WatabeNorio NonomuraKatsuhiko SaitoKota YokoyamaKen YamagiwaTakuya AdachiYuji KojimaSoichiro YoshidaYasuhisa Fujii

Published in: Japanese journal of clinical oncology (2023)

Our study revealed that 18F-PSMA 1007 was safe, well tolerated and showed high accuracy in the diagnosis of prostate cancer.

Keyphrases

pet ct
prostate cancer
radical prostatectomy
positron emission tomography
end stage renal disease
newly diagnosed
clinical trial
study protocol
pet imaging
prognostic factors
randomized controlled trial
phase iii
patient reported outcomes
benign prostatic hyperplasia
open label
placebo controlled